Cargando…
Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium
Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and thera...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596690/ https://www.ncbi.nlm.nih.gov/pubmed/36229581 http://dx.doi.org/10.1038/s41416-022-02000-4 |
_version_ | 1784815920024125440 |
---|---|
author | Fonseca, Adriana Lobo, João Hazard, Florette K. Gell, Joanna Nicholls, Peter K. Weiss, Robert S. Klosterkemper, Lindsay Volchenboum, Samuel L. Nicholson, James C. Frazier, A. Lindsay Amatruda, James F. Bagrodia, Aditya Lockley, Michelle Murray, Matthew J. |
author_facet | Fonseca, Adriana Lobo, João Hazard, Florette K. Gell, Joanna Nicholls, Peter K. Weiss, Robert S. Klosterkemper, Lindsay Volchenboum, Samuel L. Nicholson, James C. Frazier, A. Lindsay Amatruda, James F. Bagrodia, Aditya Lockley, Michelle Murray, Matthew J. |
author_sort | Fonseca, Adriana |
collection | PubMed |
description | Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and therapeutic advances. Moreover, patients with GCTs are treated by different medical professionals including paediatric oncologists, neuro-oncologists, medical oncologists, neurosurgeons, gynaecological oncologists, surgeons, and urologists. Silos of care have thus formed, further hampering knowledge dissemination between specialists. Dedicated biobank specimen collection is therefore critical to foster continuous growth in our understanding of similarities and differences by age, gender, and site, particularly for rare cancers such as GCTs. Here, the Malignant Germ Cell International Consortium provides a framework to create a sustainable, global research infrastructure that facilitates acquisition of tissue and liquid biopsies together with matched clinical data sets that reflect the diversity of GCTs. Such an effort would create an invaluable repository of clinical and biological data which can underpin international collaborations that span professional boundaries, translate into clinical practice, and ultimately impact patient outcomes. |
format | Online Article Text |
id | pubmed-9596690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95966902022-10-27 Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium Fonseca, Adriana Lobo, João Hazard, Florette K. Gell, Joanna Nicholls, Peter K. Weiss, Robert S. Klosterkemper, Lindsay Volchenboum, Samuel L. Nicholson, James C. Frazier, A. Lindsay Amatruda, James F. Bagrodia, Aditya Lockley, Michelle Murray, Matthew J. Br J Cancer Perspective Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and therapeutic advances. Moreover, patients with GCTs are treated by different medical professionals including paediatric oncologists, neuro-oncologists, medical oncologists, neurosurgeons, gynaecological oncologists, surgeons, and urologists. Silos of care have thus formed, further hampering knowledge dissemination between specialists. Dedicated biobank specimen collection is therefore critical to foster continuous growth in our understanding of similarities and differences by age, gender, and site, particularly for rare cancers such as GCTs. Here, the Malignant Germ Cell International Consortium provides a framework to create a sustainable, global research infrastructure that facilitates acquisition of tissue and liquid biopsies together with matched clinical data sets that reflect the diversity of GCTs. Such an effort would create an invaluable repository of clinical and biological data which can underpin international collaborations that span professional boundaries, translate into clinical practice, and ultimately impact patient outcomes. Nature Publishing Group UK 2022-10-13 2022-11-01 /pmc/articles/PMC9596690/ /pubmed/36229581 http://dx.doi.org/10.1038/s41416-022-02000-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Perspective Fonseca, Adriana Lobo, João Hazard, Florette K. Gell, Joanna Nicholls, Peter K. Weiss, Robert S. Klosterkemper, Lindsay Volchenboum, Samuel L. Nicholson, James C. Frazier, A. Lindsay Amatruda, James F. Bagrodia, Aditya Lockley, Michelle Murray, Matthew J. Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title | Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title_full | Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title_fullStr | Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title_full_unstemmed | Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title_short | Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium |
title_sort | advancing clinical and translational research in germ cell tumours (gct): recommendations from the malignant germ cell international consortium |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596690/ https://www.ncbi.nlm.nih.gov/pubmed/36229581 http://dx.doi.org/10.1038/s41416-022-02000-4 |
work_keys_str_mv | AT fonsecaadriana advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT lobojoao advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT hazardflorettek advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT gelljoanna advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT nichollspeterk advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT weissroberts advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT klosterkemperlindsay advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT volchenboumsamuell advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT nicholsonjamesc advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT frazieralindsay advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT amatrudajamesf advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT bagrodiaaditya advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT lockleymichelle advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium AT murraymatthewj advancingclinicalandtranslationalresearchingermcelltumoursgctrecommendationsfromthemalignantgermcellinternationalconsortium |